Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial

OBJECTIVE: To estimate the incremental cost-effectiveness of infliximab versus conventional combination treatment over 21 months in patients with methotrexate-refractory early rheumatoid arthritis. METHODS: In this multicentre, two-arm, parallel, randomised, active-controlled, open-label trial, rheu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Rheum Dis
Asıl Yazarlar: Eriksson, Jonas K, Karlsson, Johan A, Bratt, Johan, Petersson, Ingemar F, van Vollenhoven, Ronald F, Ernestam, Sofia, Geborek, Pierre, Neovius, Martin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2015
Konular:
Clinical and Epidemiological Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431324/
https://ncbi.nlm.nih.gov/pubmed/24737786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2013-205060
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller